Next stop Biogen: Carl Icahn's fight for seats on the board of Biogen Idec (BIIB) comes to a...
Next stop Biogen: Carl Icahn's fight for seats on the board of Biogen Idec (BIIB) comes to a vote Wednesday, June 3. He owns 5.6% of the biotech group. Proxy advisory service RiskMetrics Group is backing two of Icahn's nominees. Icahn gained a seat on Amylin's (AMLN) board this week and is lobbying to ouster top management at Enzon (ENZN).
From other sites
Video at CNBC.com (Sep 9, 2015)
Video at CNBC.com (Aug 21, 2015)
at CNBC.com (Jun 1, 2015)
Video at CNBC.com (May 26, 2015)
Video at CNBC.com (Mar 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs